Alkermes Plc. (ALKS): Richard F Pops , Director and CEO, Alkermes plc of Alkermes Plc. sold 25,000 shares on Apr 12, 2016. The Insider selling transaction was reported by the company on Apr 13, 2016 to the Securities and Exchange Commission. The shares were sold at $38.00 per share for a total value of $944,839.31 according the SEC Form 4 Filing.
Company has been under the radar of several Street Analysts.Alkermes Plc is Reiterated by Leerink Partners to Outperform while Lowering the Price Target of the company shares to $ 58 from a previous price target of $84 . The Rating was issued on Jan 21, 2016.Alkermes Plc is Downgraded by Morgan Stanley to Underweight. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Jan 21, 2016.Alkermes Plc is Downgraded by JP Morgan to Neutral. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Jan 21, 2016.
Currently the company Insiders own 4.25% of Alkermes Plc shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by 6.36%.Institutional Investors own 93.93% of Alkermes Plc shares.During last six month period, the net percent change held by insiders has seen a change of -1.95%.
Shares of Alkermes Plc (ALKS) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.09 points or -0.23% at $38.31 with 15,15,652 shares getting traded. Post opening the session at $38.66, the shares hit an intraday low of $37.51 and an intraday high of $39.24 and the price vacillated in this range throughout the day. The company has a market cap of $5,775 M and the number of outstanding shares has been calculated to be 15,07,41,620 shares. The 52-week high of Alkermes Plc is $80.71 and the 52-week low is $27.14.
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching developing and commercializing both with partners and on its own pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders such as addiction schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil ALKS 5461 ALKS 3831 ALKS 8700 and RDB 1419. The Company’s main marketed products include RISPERDAL CONSTA INVEGA SUSTENNA/XEPLION AMPYRA/FAMPYRA BYDUREON and VIVITROL.